RxDoctor Payments Data

Sharmineh Shams, MD

Internal Medicine · Visalia, CANPI 1447522172

Payments from drug & device makers

$742in general payments, 2019–2025

Across 55 payments — averaging $13.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$374
  • Novo Nordisk$263
  • AstraZeneca$38
  • Edwards Lifesciences$20
  • Merck$17
  • Boehringer Ingelheim$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$92,440
Medicare patients
285
Services billed
2,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$89,334
EliquisApixaban42$50,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,246
JardianceEmpagliflozin17$29,087
FarxigaDapagliflozin Propanediol18$21,245
JanuviaSitagliptin Phosphate15$20,845
MyrbetriqMirabegron22$18,749
Tresiba Flextouch U-100Insulin Degludec12$5,434
Varenicline Tartrate11$3,708
Levothyroxine Sodium246$2,858
Atorvastatin Calcium420$2,726
Memantine Hcl ErMemantine Hcl11$2,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,309
Gabapentin209$2,305
Wixela InhubFluticasone Propion/Salmeterol11$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$263$89,33480 claims
GSKTrelegy Ellipta$374$32,24636 claims
Boehringer IngelheimJardiance$16$29,08717 claims
AstraZenecaFarxiga$38$21,24518 claims
MerckJanuvia$17$20,84515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →